Los Angeles Capital Management LLC Sells 18,155 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Los Angeles Capital Management LLC decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 16.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 92,475 shares of the biopharmaceutical company’s stock after selling 18,155 shares during the period. Los Angeles Capital Management LLC’s holdings in Halozyme Therapeutics were worth $4,421,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in HALO. Hussman Strategic Advisors Inc. raised its position in Halozyme Therapeutics by 75.0% in the 4th quarter. Hussman Strategic Advisors Inc. now owns 73,500 shares of the biopharmaceutical company’s stock worth $3,514,000 after purchasing an additional 31,500 shares during the period. Private Advisor Group LLC lifted its holdings in shares of Halozyme Therapeutics by 23.8% during the fourth quarter. Private Advisor Group LLC now owns 29,908 shares of the biopharmaceutical company’s stock valued at $1,430,000 after purchasing an additional 5,745 shares during the last quarter. Convergence Investment Partners LLC raised its position in shares of Halozyme Therapeutics by 25.9% in the 4th quarter. Convergence Investment Partners LLC now owns 34,713 shares of the biopharmaceutical company’s stock worth $1,660,000 after purchasing an additional 7,151 shares during the last quarter. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $69,000. Finally, State of New Jersey Common Pension Fund D lifted its stake in Halozyme Therapeutics by 0.6% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock valued at $2,279,000 after acquiring an additional 302 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now owns 185,453 shares in the company, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,697 shares of company stock worth $1,461,001 in the last quarter. 2.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently commented on the company. Benchmark reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company reduced their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Finally, HC Wainwright increased their price target on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $57.70 on Friday. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $65.53. The stock’s 50-day simple moving average is $54.08 and its 200-day simple moving average is $54.71. The company has a market capitalization of $7.11 billion, a price-to-earnings ratio of 16.82, a PEG ratio of 0.42 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.